Gayatri BioOrganics Confirms Non-Large Corporate Status, Zero Debt Issued in FY26

Gayatri BioOrganics has confirmed it is not classified as a 'Large Corporate' (LC) for FY2025-26 and FY2026-27. Actual borrowing through debt securities for FY2025-26 was nil, meaning associated SEBI mandates are not applicable.

Company Filing

Gayatri BioOrganics Limited reported to the BSE on May 1, 2026, that it is not classified as a 'Large Corporate' under SEBI's framework for FY2025-26 and FY2026-27. This clarification follows SEBI's circular dated October 19, 2023, concerning debt fundraising by large companies.

The company reported zero actual borrowing through debt securities in FY2025-26. Consequently, mandatory borrowing requirements and any associated penalties do not apply to Gayatri BioOrganics for these periods.

SEBI's Large Corporate Framework

SEBI's 'Large Corporate' framework requires certain listed entities with substantial borrowings and strong credit ratings to raise a minimum percentage of their funds via debt securities, aiming to deepen the corporate bond market.

By confirming its non-LC status, Gayatri BioOrganics avoids these specific compliance obligations, disclosure requirements, and potential penalties related to debt issuance. This means the company does not meet the threshold criteria for outstanding long-term borrowings or credit ratings required to be classified as an LC under current SEBI norms.

Background and Rating Issues

SEBI's definition of a 'Large Corporate' typically includes listed entities with outstanding long-term borrowing of Rs. 1000 crore or more and a credit rating of 'AA' or above. The framework, revised in October 2023, aims to streamline fundraising and develop the debt market.

Notably, a disclosure from April 2023 showed Gayatri BioOrganics with Rs. 1.78 crore in outstanding borrowing and an 'NA' credit rating, yet it then confirmed itself as a Large Corporate. This prior self-classification differs from its current confirmation of non-LC status.

Adding to its financial profile, CARE Ratings placed Gayatri BioOrganics in the 'issuer non-cooperating' category in January 2024 for failing to provide required information for rating reviews. This non-cooperation status impacts its creditworthiness and ability to secure financing.

Impact of Non-LC Status

• Gayatri BioOrganics is not subject to SEBI's mandatory debt issuance norms for 'Large Corporates'.
• The company avoids specific disclosure requirements related to the LC framework.
• Compliance burdens and potential penalties associated with LC debt fundraising are bypassed.
• The company's financing strategy can continue without meeting SEBI's LC debt allocation targets.

Potential Risks

• CARE Ratings' 'issuer non-cooperating' status raises concerns about the company's transparency and credit quality, potentially affecting future borrowing capacity.
• The low level of debt, as indicated by past disclosures, and zero debt securities borrowing in FY25-26, may limit future financing options if significant capital is required.
• Clarity on the company's current total long-term borrowing relative to the Rs. 1000 crore LC threshold remains key.

Comparison to Peers

Companies classified as 'Large Corporates' under SEBI rules must adhere to specific debt fundraising obligations. Gayatri BioOrganics' current non-LC status exempts it from managing these mandates, unlike larger peers who might face these requirements. However, direct peer comparison on this compliance aspect is limited given the company's specific situation and past credit rating issues.

Future Outlook

• Any update or resolution regarding CARE Ratings' 'issuer non-cooperating' status.
• Future financial disclosures to understand the company's overall borrowing levels and creditworthiness.
• Any further clarification from SEBI or the company regarding LC classification criteria and its applicability.
• The company's strategy for future capital raising and its ability to access debt markets.